Login
SPRUCE BIOSCIENCES, INC. logo

SPRUCE BIOSCIENCES, INC.

sprucebio.com

What Do They Do?

Develops investigational therapies for neurological disorders, including TA-ERT for patients with MPS IIIB.

Who Are Their Customers?

Patients with MPS IIIB are treated by a small set of specialists. Spruce plans to market TA-ERT through its own U.S. commercial team and use regional collaborators and distributors in other markets.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −192% (Loss)
vs −$8.2M in Q3 FY2025
  • Nov 9, 2026 CRHX-101 program separated into Adrenyx Biosciences Spruce said the separation lets it focus its team and capital on TA-ERT, while shareholders retain a direct stake through a planned stock distribution.
  • Mar 16, 2026 Spruce and Kaken agreed to terminate their tildacerfont deal The agreement ends the Japan license and cancels Spruce's right to unearned milestones and royalties.

From endocrine to neurological focus The older report centered on tildacerfont for rare endocrine disorders, especially classic CAH; the latest centers on TA-ERT for MPS IIIB, while also listing a preclinical CAH program.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support